• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Oramed touts phase Ib data for type 2 diabetes capsule

November 29, 2016 By Sarah Faulkner

Oramed touts phase Ib data for type 2 diabetes capsuleOramed Pharmaceuticals (NSDQ:ORMP) said today that it finished a phase Ib study of its oral GLP-1 analog capsule for type 2 diabetes.

Glucagon-like peptide-1 (GLP-1) is a hormone that stimulates the pancreas to secrete insulin. Exenatide, a GLP-1 analog, is available on the market as an injection for patients with type 2 diabetes. The analog stimulates insulin release at increased glucose levels and can result in reduced food intake, along with weight loss.

Israel-based Oramed reported that its oral GLP-1 analog capsule could increase patient compliance to a regimen. The oral formulation is based on the company’s Protein Oral Delivery (POD) technology. Oramed is also working on an ingestible insulin capsule for patients with diabetes.

Data from the phase Ib study of the company’s GLP-1 analog capsule demonstrated that the therapy was safe and well tolerated, with no serious adverse events reported during the trial. Oramed also reported that the active oral GLP-1 arms of the study showed encouraging trending efficacy.

“We are very pleased with both the safety and efficacy results observed during this study,” CEO Nadav Kidron said in prepared remarks. “Currently we are preparing to submit an IND with the FDA and anticipate initiating a Phase IIb study in 2017.”

ORMP shares were trading at $6.20 apiece in mid-afternoon trading activity today, up +1.6%.

Filed Under: Clinical Trials, Diabetes, Featured, Food & Drug Administration (FDA), Pharmaceuticals Tagged With: Oramed Therapeutics

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS